Kiniksa Pharmaceuticals Ltd reports results for the quarter ended in June - Earnings Summary

Kiniksa Pharmaceuticals International

25/07/2023 14:31

* Kiniksa Pharmaceuticals Ltd  KNSA.OQ  reported quarterly
adjusted earnings of 21 cents​​ per share for the quarter ended
in June. The mean expectation of four analysts for the quarter
was for a loss of 17 cents per share.
    * Revenue rose 165% to $71.47 million from a year ago;
analysts
expected $52.20 million. 
    * Kiniksa Pharmaceuticals Ltd's reported EPS for the quarter
was
21 cents​.
    * The mean earnings estimate of analysts had risen by
about 17.3%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Kiniksa Pharmaceuticals Ltd shares had risen by 6.1% this
quarter and lost 0.3% so far this year.
    * The company reported quarterly net income of $14.97
million.
    * Wall Street's median 12-month price target for Kiniksa
Pharmaceuticals Ltd is $21.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data July
25 at 01:30 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.17          0.21           Beat
 Mar. 31 2023      -0.21          -0.18          Beat
 Dec. 31 2022      -0.23          0.06           Beat
 Sep. 30 2022      0.78           3.18           Beat